I know everyone and thanks for taking my question. I have only two left. Could you please reiterate on the indication space you're looking for tafasitamab. I noticed that in your previous presentation, you listed, for example, follicular lymphoma also as an indication, now it's only CLL. And for the second question, could you give us an update or news or some feedback on the expanded access program you received for tafasitamab in the U.S.